Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluidigm Reports Strong Q1 2013 Results

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Revenue up 33% and margins increase 300 basis points compared to Q1 2012.

Fluidigm Corporation has announced its financial results for the first quarter ended March 31, 2013.

Total revenue for the first quarter of 2013 was $14.5 million, an increase of 33% from $10.9 million in the first quarter of 2012. Product margin was 70% in the first quarter of 2013, compared to 67% in the first quarter of 2012.

Net loss for the first quarter of 2013 was $3.6 million, compared to a net loss of $6.7 million in the first quarter of 2012.

Non-GAAP net loss for the first quarter of 2013 was $3.5 million, compared with $4.9 million non-GAAP net loss for the first quarter of 2012 (see accompanying table for reconciliation of GAAP and non-GAAP measures).

“Our revenue from single-cell genomics applications nearly doubled year-over-year, primarily due to sales of our C1™ Single-Cell Auto Prep System. In addition, single-cell gene expression motivated about 70% of our BioMark™ HD sales. We continue to see a fundamental shift occurring in the genomics market from studying bulk, heterogeneous cell samples to analyzing individual cells, and Fluidigm is emerging as the leader in this exciting new market,” said Gajus Worthington, Fluidigm President and Chief Executive Officer.

Worthington continued, “Increased sales to high-throughput production genomics customers in agricultural and clinical laboratory settings also contributed to growth in the quarter,” continued Worthington.

Financial Highlights and Analysis
• Fluidigm’s instrument installed base expanded to approximately 720 units at the end of Q1 2013.
• Analytical systems (BioMark, BioMark HD, and EP1™) represented 64% of the installed base and preparatory systems (Access Array™ and C1) represented the remainder.
• Instrument revenue grew 34% year-on-year in the quarter, driven largely by sales of the C1 Single-Cell Auto Prep System.
• Consumables revenue grew 31% year-on-year in the quarter, driven by high-throughput production genomics customers.
• Consumables pull-through was within its historical range of $40,000 - $50,000 per instrument/year for analytical systems, and was slightly above its historical range of $10,000 - $15,000 per instrument/year for preparatory systems.
• Geographic revenue as a percent of total product revenue in the first quarter of 2013 was as follows: United States - 49%; Europe - 25%; Asia-Pacific - 13%; Japan - 10%; and Other - 3%.
• Fluidigm ended the first quarter of 2013 with approximately $86.9 million in cash, cash equivalents, and investments.
• Fluidigm received approximately $3.1 million in cash for its minority equity interest in Verinata Health, Inc. in connection with Verinata’s acquisition by Illumina, Inc.
• Excluding the proceeds from the sale of the Verinata investment, Fluidigm was cash flow neutral for the first time in any quarterly period in the company’s history.

Business Highlights Since Fluidigm’s Last Earnings Release
• The Sanger Institute-EBI Single Cell Genomics Centre, which was launched in April 2013, ordered a C1 Single-Cell Auto Prep System and a BioMark HD System to support its single-cell genomics research.
• Twelve single-cell publications referenced Fluidigm in the quarter, up from six the previous quarter. The total number of single-cell publications referencing Fluidigm is now over 70.
• HLA typing emerged as a high-throughput production genomics application for Fluidigm’s Access Array System. The DKMS Life Science Lab (Deutsche Knochenmarkspenderdatei gemeinnützige Gesellschaft mbH) scaled its HLA typing operations to thousands of samples per week using Fluidigm’s Access Array Systems. Separately, a peer-reviewed publication in Tissue Antigens authored by Roche scientists delineated the value of the Access Array System for high-throughput HLA typing with NGS systems.
• Fluidigm experienced growing demand for its custom assays business, in particular SNPtype™ assays, driven by production genomics customers.

Financial Outlook
Fluidigm is maintaining its 2013 total revenue growth guidance of 22%-26% over 2012. Historically, Fluidigm’s product revenues have tended to be lowest in the first quarter of the year and highest in the fourth quarter of the year. This trend is expected to continue in 2013.

Operating expenses in 2013 are projected to be between $63 million and $66 million. Stock compensation expense is projected to be between $5.5 million and $6.5 million. Capital spending is projected to be between $4 million and $5 million.

Total cash flow is expected to be negative for 2013. We expect to break even at the EBITDA level at quarterly revenue of approximately $20 million.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluidigm, OpGen Collaborate
Fluidigm and OpGen have announced an agreement to collaborate on instruments and kits to test for multi-drug resistance genes in bacteria, fungi, and viruses.
Tuesday, July 14, 2015
Early Access Program for Fluidigm's New Imaging Mass Cytometry Platform
Prototypes of the product are expected to begin shipping to early access partners by the end of this year.
Sunday, August 03, 2014
Revealing the Role of “Precocious” Dendritic Cells in Inflammatory Response
Discovery makes it possible for researchers to explore how these “precocious” cells escalate the body’s immune response when the body is under attack.
Monday, July 07, 2014
Fluidigm to Acquire DVS Sciences
The acquisition consideration of approximately $207.5 million consists of a combination of Fluidigm common stock and cash.
Wednesday, January 29, 2014
Fluidigm to Develop and Supply a Custom High-throughput Prep System for HLA Typing
Custom system will ultimately enable DKMS Life Science Lab to type several thousand samples per week.
Friday, May 03, 2013
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
Fluidigm Announces Unrestricted Sales into Prenatal Health
Fluidigm collaboration ends.
Tuesday, June 19, 2012
New Research Center to Focus on Mammalian Single Cell Genomics
New Center will feature a complete suite of Fluidigm single-cell tools, protocols and technologies.
Friday, June 15, 2012
Fluidigm Reports Financial Results for First Quarter 2012
Q1 total revenue up 26% compared to Q1 2011.
Monday, May 14, 2012
Fluidigm China Opens Its Doors
Company expects to rapidly build strong presence in country and improve services to Chinese customer base.
Monday, April 23, 2012
Fluidigm and AH Diagnostics Sign Distribution Deal for Scandinavia
AH diagnostics will offer Fluidigm's complete portfolio, including the complete line up of Dynamic Array(TM), Digital Array(TM) and Access Array IFCs for real-time PCR, digital PCR, single-cell gene expression, sample preparation for next-generation sequencing, and SNP genotyping.
Tuesday, January 31, 2012
Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties
Fluidigm Corporation announces that it has entered into a set of cross-licensing and sub-licensing agreements on a range of intellectual properties with Life Technologies.
Tuesday, July 12, 2011
Fluidigm Reports Financial Results for First Quarter 2011
Total revenue for the first quarter of 2011 was $8.7 million, an increase of 30% from $6.7 million in the first quarter of 2010.
Wednesday, May 11, 2011
Fluidigm Announce Israeli Distribution Deal
Fluidigm has appointed Eisenberg Brothers as distributor in Israel and Eisenberg Brothers offers Fluidigm's complete portfolio of BioMark™, EP1™, and Access Array™ systems.
Tuesday, March 01, 2011
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
How Cholesterol Leads to Clogged Arteries
A new study shows that when immune cells called neutrophils are exposed to cholesterol crystals, they release large extracellular web-like structures that trigger the production of inflammatory molecules linked to artherosclerosis.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Researchers Discover New Type of Mycovirus
Virus infects the fungus Aspergillus fumigatus, which can cause the human disease aspergillosis.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!